These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 18020622)

  • 1. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
    Jurk M; Vollmer J
    BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single Stranded DNA Immune Modulators with Unmethylated CpG Motifs: Structure and Molecular Recognition by Toll-Like Receptor 9.
    Fehér K
    Curr Protein Pept Sci; 2019; 20(11):1060-1068. PubMed ID: 31470785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.
    Murad YM; Clay TM
    BioDrugs; 2009; 23(6):361-75. PubMed ID: 19894778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma.
    Gupta GK; Agrawal DK
    BioDrugs; 2010 Aug; 24(4):225-35. PubMed ID: 20623989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
    Vollmer J; Krieg AM
    Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
    Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
    Front Immunol; 2019; 10():179. PubMed ID: 30800129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
    Becker Y
    Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiinfective applications of toll-like receptor 9 agonists.
    Krieg AM
    Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.
    Hanagata N
    Int J Nanomedicine; 2012; 7():2181-95. PubMed ID: 22619554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of Toll-like receptor 9 activation.
    Krieg AM
    Nat Rev Drug Discov; 2006 Jun; 5(6):471-84. PubMed ID: 16763660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
    Vollmer J
    Expert Opin Biol Ther; 2005 May; 5(5):673-82. PubMed ID: 15934842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
    Murad YM; Clay TM; Lyerly HK; Morse MA
    Expert Opin Biol Ther; 2007 Aug; 7(8):1257-66. PubMed ID: 17696823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance.
    Berghöfer B; Frommer T; König IR; Ziegler A; Chakraborty T; Bein G; Hackstein H
    Clin Exp Allergy; 2005 Sep; 35(9):1147-54. PubMed ID: 16164440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
    Mutwiri G
    Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
    El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
    Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
    Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
    J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.